(AOF) – Affluent Medical announces the completion of bridge financing of 3.5 million euros with its main shareholders. This medtech in the clinical phase specializing in the international development and industrialization of innovative medical prostheses specifies that this financing was carried out in the form of a capital increase with removal of shareholders’ preferential subscription rights for the benefit of a category of beneficiaries. Participating shareholders are Truffle Capital, LCEA, Ginko Invest, Denos and Hayk Holding.
The transaction will allow the company to finance its operational needs, in particular by covering the costs related to regulatory support for interactions with the FDA concerning Kalios, by initiating the pilot study in humans for Artus and by continuing the study driver for Epygon.
Affluent underlines that taking into account this bridging financing, its financial horizon is extended until May 2024 “without impacting operational activities”.
The operation will result in the issue of approximately 2.244 million new ordinary shares, representing 7.26% of the current share capital and a shareholder who held 1% of the company’s capital before the capital increase will see his participation reduced to 0.93% after the operation.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
